Molecular pathogenesis of sporadic colorectal cancers by unknown
Yamagishi et al. Chin J Cancer  (2016) 35:4 
DOI 10.1186/s40880-015-0066-y
REVIEW
Molecular pathogenesis of sporadic 
colorectal cancers
Hidetsugu Yamagishi1, Hajime Kuroda2, Yasuo Imai1,3* and Hideyuki Hiraishi4
Abstract 
Colorectal cancer (CRC) results from the progressive accumulation of genetic and epigenetic alterations that lead to 
the transformation of normal colonic mucosa to adenocarcinoma. Approximately 75% of CRCs are sporadic and occur 
in people without genetic predisposition or family history of CRC. During the past two decades, sporadic CRCs were 
classified into three major groups according to frequently altered/mutated genes. These genes have been identified 
by linkage analyses of cancer-prone families and by individual mutation analyses of candidate genes selected on the 
basis of functional data. In the first half of this review, we describe the genetic pathways of sporadic CRCs and their 
clinicopathologic features. Recently, large-scale genome analyses have detected many infrequently mutated genes as 
well as a small number of frequently mutated genes. These infrequently mutated genes are likely described in a lim-
ited number of pathways. Gene-oriented models of CRC progression are being replaced by pathway-oriented models. 
In the second half of this review, we summarize the present knowledge of this research field and discuss its prospects.
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Introduction
Colorectal cancer (CRC) is the third most common can-
cer and the fourth leading cause of cancer-related death 
worldwide [1, 2]. In 2012, 1,360,600 new cases were 
diagnosed and 693,900 deaths were attributed to CRC 
[2]. CRCs occur sporadically in the majority of cases, 
and only 5%–10% are due to inherited mutations in 
well-known cancer-related genes. However, up to 25% 
of patients have a family history of CRC, suggesting a 
specific contribution by genes that have yet to be identi-
fied [3]. CRCs develop from normal colonic mucosa via 
progressive accumulation of genetic alterations, such as 
mutations in adenomatous polyposis coli (APC) during 
earlier stages and mutations in rat sarcoma viral onco-
gene homolog (RAS) and tumor protein 53 (TP53) during 
later stages [4]. However, one study reported that muta-
tions of all three genes were found in only 7% of CRCs, 
suggesting that other genes may be involved in the tumo-
rigenic process [5]. Genomic instability is a fundamental 
process in colorectal carcinogenesis [6], as demonstrated 
in a number of inherited CRCs, such as hereditary non-
polyposis colon cancer/Lynch syndrome and Mut YH-
associated polyposis [3, 7], which are caused by germ-line 
mutations of genes involved in DNA replication and 
repair. Chromosomal instability (CIN) is a process that 
generates gene deletions, duplications, and chromo-
somal rearrangements. CIN is the most common type 
of genomic instability, occurring in 70%–85% of CRCs, 
mainly in tumors proficient in DNA mismatch repair 
(MMR) [8]. Microsatellite instability (MSI) is caused by 
DNA MMR deficiency and is characterized by frequent 
mutations at simple nucleotide repeat sequences [9]. MSI 
accounts for approximately 15% of sporadic CRCs. CpG 
island methylator phenotype (CIMP) is also described 
as an epigenetic instability that influences CRC patho-
genesis [10–12]. One type of genomic instability usu-
ally predominates in the development of a specific CRC, 
although MSI and CIMP often coexist [13]. In the first 
half of this review, we describe the genetic pathways of 
sporadic CRCs and their clinicopathologic features.
Recently, large-scale genome analyses have detected 
many infrequently mutated genes, as well as a small 
number of frequently mutated genes. Although the data 
obtained are enormous and complex, many infrequently 
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mutated genes are likely described in a limited number of 
pathways. Gene-oriented models of CRC progression are 
being replaced by pathway-oriented models. In the sec-
ond half of this review, we summarize the present molec-
ular genetics of sporadic CRCs clarified by the recent 
advances of genome analytical techniques.
Three major genetic pathways for sporadic CRCs
Sporadic CRCs occur in patients who have a median age 
of 70–75 years, and approximately 70% of CRCs develop 
in the distal colon. Many differences in clinicopathologic 
features exist between the proximal and distal colons. 
Genetically, sporadic CRCs develop by the accumula-
tion of a series of abnormalities in tumor suppressor 
genes and oncogenes. Several investigators have postu-
lated the adenoma-carcinoma sequence theory, in which 
APC mutation serves as an initiating event, followed by 
the accumulation of multiple mutations of genes, such 
as Kirsten RAS (KRAS), Sma- and Mad-related protein 4 
(SMAD4), and TP53 [4, 14, 15]. According to this model, 
at least seven distinct mutations are required for CRC 
pathogenesis. Other investigators have described another 
route to colorectal carcinogenesis through serrated pol-
yps [16].
Presently, three major distinct genetic pathways to 
CRC have been postulated. Approximately 70% of spo-
radic CRCs develop along the CIN pathway. These can-
cers are characterized by the accumulation of numerical 
or structural chromosomal abnormalities, resulting in 
aneuploid karyotype, frequent loss-of-heterozygosity 
(LOH) at tumor suppressor gene loci, and chromosomal 
rearrangements [17]. Moreover, CIN tumors are dis-
tinguished by the accumulation of mutations in specific 
oncogenes and tumor suppressor genes [e.g., APC, KRAS, 
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic 
subunit alpha (PIK3CA), B-Raf proto-oncogene, serine/
threonine kinase (BRAF), SMAD4, and TP53], thereby 
activating pathways critical for carcinogenesis.
Another important pathway is the MSI pathway, caused 
by dysfunction of DNA MMR genes. MSI is found in 
15% of sporadic CRCs. Unlike Lynch syndrome that is 
caused by germ-line mutations of MMR genes, such as 
MutL homolog 1 (MLH1) (32% of cases), MutS homolog 
2 (MSH2) (39%), postmeiotic segregation increased 2 
(PMS2) (15%), and MSH6 (14%) [18], MMR deficiency 
in sporadic CRCs is due mainly to silencing of the MMR 
genes, mostly MLH1 (>80% of cases), by promoter hyper-
methylation [19, 20]. Usually, expression is lost in the case 
of MLH1 and MSH2 and their binding partners (MSH6 
and PMS2, respectively). Classification of MSI is based 
on altered size of various mono- and di-nucleotide repeat 
sequences, such as BAT25, BAT26, D2S123, D5S346, and 
D17S250, known as the Bethesda panel [21, 22]. Altered 
size of at least two of the five microsatellite panel markers 
is defined as MSI-high (MSI-H). Sporadic MSI-H is asso-
ciated with CIMP. Most MSI-H CRCs are diploid or near 
diploid, and LOH is rare. CRCs with one abnormal marker 
in the panel are termed MSI-low (MSI-L), and their clini-
cal significance is controversial. MSI-L is often grouped 
with microsatellite-stable (MSS) tumors. MSI-H tumors 
frequently have frameshift mutations in those genes that 
contain small runs of nucleotide repeats in exon-coding 
regions, such as transforming growth factor-β recep-
tor 2 (TGFBR2), insulin-like growth factor 2 receptor 
(IGF2R), E2F transcription factor 4, p107/p130-binding 
(E2F4), MSH6, MSH3, and caspase 5 (CASP5) [23–28]. 
An (A)10 repeat of the TGFBR2 gene is mutated in 80% of 
MSI-H CRCs. In MSI-H tumors, APC and BRAF are often 
mutated, but KRAS mutation is rare. Sporadic MSI-H 
CRCs, as well as those with Lynch syndrome, are char-
acterized by right-sided location, mucinous or medullary 
type, and presence of tumor-infiltrating lymphocytes, ear-
lier stages, and better prognoses [29, 30].
The third pathway, designated as CIMP, is charac-
terized by a widespread CpG island methylation [10]. 
Approximately 30%–40% of sporadic proximal CRCs are 
CIMP-positive, compared with 3%–12% of distal CRCs 
[31–33]. CIMP-positive CRCs often have MSI-H due to 
methylation of the MLH1 promoter, but more than 50% 
of CIMP tumors are MSS. CIMP is uncommon in Lynch 
syndrome that exhibits MSI [11, 34]. CIMP is also associ-
ated with BRAF mutations in both MSI and MSS CRCs 
[11, 35]. No consensus exists yet for what constitutes 
the optimal panel of CpG sites for CIMP determination. 
The classic panel consists of CpG sites in MLH1, cyc-
lin-dependent kinase inhibitor 2A (CDKN2A, p16), and 
methylated in tumors (MINTS) 1, 2, and 31 [36]. CIMP-
positive tumors based on the classic panel can be divided 
in two types, namely CIMP-high, related to BRAF muta-
tions and MLH1 methylation, and CIMP-low, related to 
KRAS mutations and MSS [37]. CIMP-negative tumors 
are MSS with frequent TP53 mutation [37, 38]. Based 
on a systematic screen of 195 CpG sites, calcium chan-
nel, voltage-dependent, T type, alpha 1G subunit (CAC-
NA1G), IGF2, neurogenin 1 (NEUROG1), runt-related 
transcription factor 3 (RUNX3), and suppressor of 
cytokine signaling 1 (SOCS1) was proposed as an alterna-
tive to the classic panel [20]. CIMP, which was defined by 
this panel, did not show a relationship to KRAS, but did 
strongly associate with BRAF V600E mutation [34, 39].
The definition of the three genetic pathways is not 
mutually exclusive, as in the case of CIMP, which often 
results in MLH1 promoter methylation and MSI. Up to 
25% of MSI CRCs can exhibit CIN [8], and concomitant 
CIMP and CIN were noted in 68 of 364 CRCs with CIN 
and 95 CRCs with CIMP [40].
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Genetic pathways and morphology
Consistent with genetic models, there appear to be at 
least three distinct clinicopathologic evolutional routes to 
sporadic CRCs [41, 42]. The first is the traditional path-
way, which starts from normal mucosa via tubular ade-
nomas (with APC mutations) and results in typical CRC 
in the distal colon (with TP53 mutation and CIN). The 
second is the serrated pathway, which starts from normal 
mucosa via serrated adenomas (with BRAF mutations 
and CIMP) and results in colon cancer in the proximal 
colon with good prognosis (with MLH1 loss and MSI). 
The third is the alternative pathway, which starts from 
normal mucosa via villous, partly serrated adenomas 
(with KRAS, BRAF, and APC mutations and CIMP) and 
results in colon cancer with poor prognosis (with CIMP). 
The traditional and serrated pathways are homogenous, 
but the alternative pathway is more heterogeneous. The 
prevalence of each pathway is estimated at 50%–70% 
(traditional), 10%–20% (serrated), and 10%–30% (alterna-
tive) [42]. In addition, superficial-type colorectal tumors 
and de novo cancer without precursor lesions have been 
identified. KRAS mutation was rare in superficial-type 
adenoma and adenocarcinoma [43, 44]. TP53 and APC 
were frequently mutated, but KRAS was not mutated in 
de novo cancers, which were also significantly associated 
with LOH at chromosome 3p [45, 46].
CRCs in the late stage acquire more aggressive pheno-
types and are more invasive and metastatic, for which 
epithelial-mesenchymal transition (EMT) has been pro-
posed as a critical step [42]. EMT represses cell adhe-
sion molecules, such as E-cadherin and zona occludens 
1, and induces mesenchymal markers, such as vimentin 
and N-cadherin. Consequently, cells acquire a fibroblast-
like appearance. Some growth factors, such as transform-
ing growth factor-β (TGF-β), appear to be responsible for 
the induction of EMT, and the wingless/int-1 (WNT)/β-
catenin signaling pathway and loss of E-cadherin are con-
sidered the major effectors of EMT. These pathways are 
summarized in Fig. 1.
The origin of CRCs in the colonic crypt has been inves-
tigated in association with these pathways, whether they 
are identical or truly different in characteristics and dif-
ferentiation status [42]. It has been suggested that tumor 
development through the traditional pathway is slow 
(5–20 years) and that the initial events occur in the fully 
differentiated cells of the colonic crypt [42]. APC muta-
tions have been detected in the cells of the upper crypt 
compartment [47], and the precursor lesions tend to 
grow upward. In contrast, tumor development through 
the serrated pathway may occur in the cells of the lower 
crypt compartment, whose functions are finely regu-
lated by epigenetic mechanisms [48–50]. The precur-
sor lesions of the serrated pathway grow downward or 
laterally, are rapidly progressive, and are prone to CIMP 
[42, 51].
Previously, hyperplastic polyps were considered non-
neoplastic, but some are now considered precursors 
of CRC. Therefore, hyperplastic polyps were renamed 
“serrated polyps,” which the World Health Organization 
now classifies three categories: hyperplastic polyps, ses-
sile serrated adenoma/polyps (SSA/Ps), and traditional 
serrated adenomas (TSAs) [16]. Hyperplastic polyps are 
most commonly located in the distal colon and typically 
exist as multiple sessile lesions of 1–5  mm in diameter. 
Histologically, the crypts are straight, and proliferation 
is located in the lower third of the crypts, with serration 
developing in the more luminal aspects [52]. SSA/Ps are 
more likely located in the proximal colon and are usu-
ally larger than hyperplastic polyps [53]. SSA/Ps, which 
comprise approximately 15%–20% of all serrated pol-
yps, are thought to be precursors of sporadic CRC with 
MSI-H (serrated pathway) and probably with CIMP-
positive MSS (alternative pathway). SSA/Ps show an 
overall distortion of crypts resulting from alterations of 
the proliferative zone, which is not located in the base of 
the crypt [52]. Crypts still reach the muscularis mucosa, 
and they are generally L-, inverted T-, or anchor-shaped. 
TSAs, which comprise less than 1% of all serrated pol-
yps, may be precursors of sporadic CRC via the alterna-
tive pathway. They are usually located in the distal colon 
and characterized by an overall complex and villiform 
growth pattern, often with cells showing cytological 
dysplasia. Ectopic crypt formation, meaning crypts that 
do not reach the muscularis mucosa, is characteristic to 
TSA. TSAs show increased methylation but never show 
methylation of MLH1. Approximately 20%–50% of TSAs 
have KRAS mutation, and 30%–70% of TSAs have BRAF 
mutations [54–56]. BRAF-mutant and KRAS-mutant 
TSAs are thought to be disparate with distinct clinico-
pathologic and molecular features, although they can-
not be distinguished morphologically. The BRAF-mutant 
TSAs, via CDKN2A silencing, represent a precursor of 
more aggressive MSS CRC [55]. Representative histolo-
gies of polyps, adenoma, and carcinoma of the colon and 
rectum are shown in Fig. 2.
Large‑scale genome analyses of sporadic CRCs
In 2007, Wood et al. [57] reported the results of exome-
wide sequencing analyses of 11 CRCs. Most of the 
mutated genes (49–111; average, 76) per colorectal tumor 
were harmless or passengers, and fewer than 15 muta-
tions were considered “driving mutations.” Non-synon-
ymous mutations in CRCs showed a strong predilection 
for C to T transitions at the CpG dinucleotides.
In 2008, Leary et al. [58] reported the data of genome-
wide copy number changes of 36 CRCs, homozygous 
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deletion and amplification. Individual CRCs had on aver-
age seven copy number alterations, i.e., four homozygous 
deletions and three amplifications. The average number 
of protein-coding genes affected by homozygous deletion 
and amplification was nine per CRC. The data were inte-
grated with those of the previous transcript mutational 
analysis [57], and candidate driver genes were identified: 
oncogenes, such as v-myc avian myelocytomatosis viral 
oncogene homolog (MYC), endothelial precursor protein 
B9 (EPPB9), epidermal growth factor receptor (EGFR), 
insulin receptor substrate 2 (IRS2), zinc finger protein 480 
(ZNF480), ZNF155, and Neugrin (NGRN), and tumor sup-
pressor genes, such as phosphatase and tensin homolog 
(PTEN), TP53, mitogen-activated protein kinase kinase 
4 (MAP2K4), SMAD2, SMAD3, ZNF521, and OMA1. A 
statistical approach was performed to examine whether 
groups of genes belonging to certain cellular pathways 
were preferentially affected by genetic alterations, and 
many genetic alterations were found to be described in 
a limited number of pathways, such as the EGFR-phos-
phatidylinositol 3-kinase (PI3K), EGFR-mitogen-activated 
protein kinase (MAPK), Notch, G1/S cell cycle transition 
pathways, cell–cell interaction and adhesion, and prote-
olysis pathways. For example, the EGFR signaling pathway 
via phosphatidylinositol(3,4,5)-triphosphate (PIP3) con-
sists of 23 genes, in which 9 were found to be altered: 12 
point mutations were found, 5 were amplified, and 6 were 
homozygously deleted. The net effect of a pathway can be 
the same whether certain components are altered by point 
mutations, amplifications, and deletions. These data sug-
gest that the gene-oriented models of cancer progression 
are being replaced by the pathway-oriented models.
Fig. 1 Evolutional pathways for colorectal morphogenesis. The traditional pathway is the most homogenous pathway, originating from tubular 
adenoma (via adenomatous polyposis coli (APC) and subsequently Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation) and leading 
to adenocarcinoma [via tumor protein 53 (TP53) mutation]. This pathway is characterized by chromosomal instability (CIN), negative CpG island 
methylator phenotype (CIMP), and average outcome. The serrated pathway is also the most homogenous pathway, originating from sessile serrated 
adenoma/polyps (SSA/P) via B-Raf proto-oncogene, serine/threonine kinase (BRAF) mutation and CIMP-high (CIMP-H) and leading to adeno-
carcinoma via MutL homolog 1 (MLH1) promoter methylation and microsatellite instability-high (MSI-H). This pathway is characterized by good 
prognosis. The alternative pathway is more heterogeneous and may arise mostly from villous adenoma and perhaps also from SSA/P and traditional 
serrated adenoma (TSA) via CIMP-low (CIMP-L) and predominant KRAS but occasional BRAF mutations. This pathway lacks CIN and has the worse 
prognosis with low responsiveness to chemotherapy. The de novo cancers usually lack KRAS mutation but are significantly associated with TP53 and 
APC mutations and also loss of heterozygosity (LOH) at chromosome 3p (chr 3p). EMT epithelial-mesenchymal transition, TGF-β transforming growth 
factor-β, MSI-L MSI-low. A part of this figure was reproduced from figure 1 in Patholog Res Int 2012;2012:509348 authored by Pancione et al. [42], 
with permission
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In 2011, Bass et al. [59] reported the results of whole-
genome sequencing of nine CRCs and paired non-neo-
plastic controls. They found 137,968 somatic mutations in 
nine MSS-CRCs, with an average of 15,330 mutations per 
tumor. Non-synonymous coding mutations were 47–147 
per tumor, with an average of 79. In the nine CRCs, they 
also found 675 genomic rearrangements (range, 5–182; 
mean, 75), of which 82% were intra-chromosomal. They 
found 11 rearrangements (2 inter- and 9 intra-chromo-
somal) that gave rise to in-frame fusion transcripts. By 
screening 97 more primary CRCs, an intra-chromosomal 
fusion on chromosome 10, vesicle transport through 
interaction with t-SNAREs 1A (VTI1A)-transcription 
factor 7-like 2 (TCF7L2), was found to be recurrently 
expressed (3% of CRCs). TCF7L2 encodes a transcrip-
tion factor TCF4 that dimerizes with β-catenin [encoded 
by catenin beta 1 (CTNNB1)] [60]. Small interfering 
RNA-mediated knockdown of VTI1A-TCF7L2 resulted 
in a reduction in the anchorage-independent growth of 
NCI-H508-derived cells, which expressed the VTI1A-
TCF7L2 fusion [59]. These data suggest that functionally 
important fusions may occur in a small proportion of this 
disease.
In 2012, the Cancer Genome Atlas Network [61] 
published the results of genome-scale analyses of 276 
CRCs, including exome sequencing, DNA copy number, 
Fig. 2 Representative histological figures of polyps, adenoma, and carcinoma of the colon and rectum (hematoxylin and eosin stain). a hyperplastic 
polyp. b sessile serrated adenoma/polyp. c tubular adenoma. d villous adenoma. e traditional serrated adenoma. f adenocarcinoma
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promoter methylation, and mRNA and microRNA 
expression. The whole-exome sequencing of 224 CRCs 
revealed that hypermutated CRC (>12 mutations/Mb) 
comprised 16% of total samples, of which three-quarters 
were expected as MSI-H, usually with MLH1 methyla-
tion; the other quarter was neither MSI-H nor CIMP but 
showed somatic mutations in one or more MMR genes 
and polymerase ε. The eight most frequently mutated 
genes among the non-hypermutated tumors (<8.24 
mutations/Mb) were APC, TP53, KRAS, PIK3CA, F-box 
and WD repeat domain containing 7 (FBXW7), SMAD4, 
TCF7L2, and NRAS. CTNNB1, SMAD2, family with 
sequence similarity 123B (FAM123B), and SRY-box 9 
(SOX9) were also mutated frequently. The eight most fre-
quently mutated genes among the hypermutated CRCs 
were BRAF (V600E), activin receptor type-2A (ACVR2A), 
APC, TGFBR2, MSH3, MSH6, solute carrier family 9, 
subfamily A (NHE9, cation proton antiporter 9), mem-
ber 9 (SLC9A9), and TCF7L2. The different sequences of 
genetic events were suggested between the two CRCs.
The Cancer Genome Atlas Network researchers inves-
tigated somatic copy number alterations in 257 tumors 
and identified potential targets of arm-level changes, 
including gains of 1q, 7p, 7q, 8p, 8q, 12q, 13q, 19q, 20p, 
and 20q, and losses of 1p, 4q, 5q, 8p, 14q, 15q, 18p and 
q including SMAD4 (in 66% of the tumors), 17p and q 
including TP53 (in 56% of the tumors), 20p, and 22q. In 
addition, they identified 28 regions of significant focal 
deletions and 17 regions of significant focal amplifica-
tions. One of the most common focal amplifications, 
found in 7% of the tumors, was a 100 to 150-kb region in 
11p15.5, which contained genes encoding IGF2 and miR-
483. IGF2 amplification/overexpression was found to be 
exclusive to the events leading to the activation of the 
PI3K pathway (IRS2 up-regulation, PIK3CA mutation, 
and PTEN homozygous deletion), suggesting the impor-
tance of the IGF2-IGF1R-IRS2 axis signals to PI3K.
In addition, they identified 250 inter-chromosomal 
translocations in 97 tumors by whole-genome sequenc-
ing. They found three cases (3%) of neuron navigator 2 
(NAV2)-TCF7L1 fusions and 21 cases (22%) of trans-
location involving tetratricopeptide repeat domain 28 
(TTC28), which is predicted to inactivate TTC28. TTC28 
is a target of TP53, and TTC28 protein inhibits tumor cell 
growth [62]. However, Pitkänen et al. [63] later reported 
that translocations involving TTC28 may be long inter-
spersed element-1 (LINE-1) transpositions originat-
ing from a LINE-1 element in the first intron of TTC28, 
and that such changes would be passengers resulting 
from promoter-hypomethylation and genetic instability 
observed in CRCs.
The recurrent genomic alterations were grouped in five 
pathways: the WNT, receptor tyrosine kinase (RTK)-RAS 
(MAPK), PI3K, TGF-β, and TP53 pathways (Table  1). 
Considerable overlap existed in the alterations of these 
pathways. The WNT pathway was altered in 93% of all 
tumors, and co-occurrence of alterations involving the 
RAS and PI3K pathways were observed in one-third of 
tumors.
Future prospects
Starting from mutational analyses of candidate genes, 
recent advances in analyzing genomic structure are greatly 
increasing our knowledge of CRC. Many infrequent gene 
alterations are going to be found. The immense complexity 
of cancer genome is somewhat misleading because most 
alterations are immaterial to neoplasia and are simply pas-
senger changes. However, some of the infrequent muta-
tions can be drivers by functioning through a much more 
limited number of the same signal transduction pathways. 
At present, all of the known driver genes for carcinogene-
sis can be classified into 12 pathways, which can be further 
classified into three core cellular processes: cell fate deter-
mination, cell survival, and genome maintenance, through 
which a growth advantage can be developed [64]. Thus, 
the gene-oriented models of cancer progression are being 
replaced by the pathway-oriented models.
The genome-wide data hitherto reported were obtained 
by analyzing CRCs in the later stage. Even the initial 
events that determine the fate of tumor cells, whether 
hypermutated or non-hypermutated, have not been elu-
cidated yet, nor has the subsequent accumulation process 
of gene mutations/genomic alterations been elucidated. 
To date, CRCs have been subclassified by pathologic 
investigation. Genetic changes that underlie specific his-
tological subtypes are largely unknown. Various stages 
of lesions must be analyzed, from normal-appearing 
epithelium to late-stage cancers. It may also be neces-
sary to analyze cells at specific sites of the crypt. In addi-
tion, little is known about genetic differences between 
Table 1 Frequencies of genetic changes leading to dereg‑
ulation of the signaling pathways in colorectal cancers
Reproduced from Fig. 4 in Nature 2012;487:330–7 authored by the Cancer 
Genome Atlas Network [61] with modifications, with permission
WNT wingless/int-1, TGF-β transforming growth factor β, PI3K 
phosphatidylinositol 3-kinase, RTK receptor tyrosine kinase, RAS rat sarcoma viral 
oncogene homolog, TP53 tumor protein 53
Pathway Frequency of genetic changes leading 
to deregulation
Non-hypermutated (%) Hypermutated (%)
WNT signaling 92 97
TGF-β signaling 27 87
PI3K signaling 50 53
RTK-RAS signaling 59 80
TP53 signaling 64 47
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cancers arising de novo and those arising via adenoma. 
The data of arm-level changes reported by the Cancer 
Genome Atlas Network did not detect loss of 3p that had 
been associated previously with de novo cancers [46, 61]. 
Further investigations will be needed to clarify the whole 
picture of molecular carcinogenesis of CRCs.
Cancer genome sequencing has already had an impact on 
the clinical care of cancer patients. The detection of acti-
vating mutations in driver genes encoding protein kinases 
has led to the development of small-molecule inhibitor 
drugs targeting those kinases. On the other hand, more 
than half of the driver genes encode tumor suppressors. 
Small-molecule drugs cannot generally replace functions of 
defective gene products resulting from mutations in tumor 
suppressor genes. However, every tumor suppressor gene 
inactivation is expected to result in the activation of some 
growth-promoting signal downstream of the pathway, such 
as PTEN mutation that results in the activation of AKT 
kinase. The whole-genome analyses in respective patients 
will identify many less frequent driver mutations, which 
will help identify potential drug targets in each patient, 
leading to more personalized cancer therapy.
Conclusions
Molecular genetics of sporadic CRCs has significantly 
advanced over the past two decades. The field has 
entered a new era, when the gene-oriented models are 
being replaced by the pathway-oriented models. Whole-
genome analyses will further provide a useful resource 
for understanding CRCs and identifying possible molec-
ular targets for their therapies.
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